drugset

drugset / Trial / NCT06921837

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

NCT06921837 ↗

Phase 1/2 Recruiting 122 enrolled Bolt Biotherapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Timeline

Start: 2025-05-26
Primary completion: 2027-05
Completion: 2029-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BDC-4182	Monoclonal antibody	—	—

Indications